产品说明书

Voglibose

Print
Chemical Structure| 83480-29-9 同义名 : AO-128
CAS号 : 83480-29-9
货号 : A214654
分子式 : C10H21NO7
纯度 : 98%+
分子量 : 267.276
MDL号 : MFCD00865496
存储条件：

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(392.85 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 250 mg/mL(935.36 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 D-Glucose and insulin levels of plasma are usually high in diabetics especially after food ingestion, and reducing intestinal carbohydrate absorption, such as monosaccharides, which are hydrolyzed by α-glucosidase, is one way to control disorders of carbohydrate metabolism. Voglibose, a α-glucosidase inhibitor, delays the digestion and absorption of carbohydrates and is the aid in the treatment of diabetes[3]. In the case of postprandial glucose excursion, oral administration of voglibose (0.2 mg/kg) reduced the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats[4]. In prediabetic db/db mice, voglibose decreased the average food consumption by 37% compared with vehicle-treated mice. Furthermore, voglibose treatment increased GLP-1 (glucagon-like peptide-1) secretion, while it decreased plasma glucose-dependent insulinotropic polypeptide (GIP)[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02456428 - Completed - Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 <<
NCT02476760 - Completed - Canada, Quebec ... 展开 >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 收起 <<
NCT02685410 HIV Prevention ... 展开 >> STI Prevention 收起 << Not Applicable Completed - United States, Connecticut ... 展开 >> Yale New Haven Hospital New haven, Connecticut, United States, 06510 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.74mL

0.75mL

0.37mL

18.71mL

3.74mL

1.87mL

37.41mL

7.48mL

3.74mL
参考文献

[1]Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem. 2006;13(1):109-16.

[2]Ikenoue T, Okazaki K, et al. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine] , on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull. 1997 Apr;20(4):354-9.

[3]Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem. 2006;13(1):109-16

[4]Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, Kondo N. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull. 1997 Apr;20(4):354-9

[5]Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab. 2010 Mar;12(3):224-33